Combined smoking and alcohol cues: Effects on craving, drug‐seeking, and consumption

2021 ◽  
Author(s):  
Courtney A. Motschman ◽  
Stephen T. Tiffany
Keyword(s):  
Drug Seeking ◽  
Alcohol Cues

The Grasp Cell Hypothesis: Near-miss effect points to common neurological machinery in posterior parietal cortex for controllable objects and concepts

2018 ◽  
Author(s):  
Imogen M Kruse
Keyword(s):  
Parietal Cortex ◽  
Posterior Parietal Cortex ◽  
Near Miss ◽  
Illusion Of Control ◽  
Gambling Behaviour ◽  
Drug Seeking ◽  
Spatial Influence ◽  
Reward Probability ◽  
Posterior Parietal ◽  
Action Value

The near-miss effect in gambling behaviour occurs when an outcome which is close to a win outcome invigorates gambling behaviour notwithstanding lack of associated reward. In this paper I postulate that the processing of concepts which are deemed controllable is rooted in neurological machinery located in the posterior parietal cortex specialised for the processing of objects which are immediately actionable or controllable because they are within reach. I theorise that the use of a common machinery facilitates spatial influence on the perception of concepts such that the win outcome which is 'almost complete' is perceived as being 'almost within reach'. The perceived realisability of the win increases subjective reward probability and the associated expected action value which impacts decision-making and behaviour. This novel hypothesis is the first to offer a neurological model which can comprehensively explain many empirical findings associated with the near-miss effect as well as other gambling phenomena such as the ‘illusion of control’. Furthermore, when extended to other compulsive behaviours such as drug addiction, the model can offer an explanation for continued drug-seeking following devaluation and for the increase in cravings in response to perceived opportunity to self-administer, neither of which can be explained by simple reinforcement models alone. This paper therefore provides an innovative and unifying perspective for the study and treatment of behavioural and substance addictions.

scholarly journals Ketogenic diet reduces alcohol withdrawal symptoms in humans and alcohol intake in rodents

2021 ◽  
Vol 7 (15) ◽  
pp. eabf6780
Author(s):  
Corinde E. Wiers ◽  
Leandro F. Vendruscolo ◽  
Jan-Willem van der Veen ◽  
Peter Manza ◽  
Ehsan Shokri-Kojori ◽  
...  
Keyword(s):  
Ketogenic Diet ◽  
Alcohol Withdrawal ◽  
Alcohol Use Disorder ◽  
Alcohol Intake ◽  
Anterior Cingulate ◽  
Dorsal Anterior Cingulate Cortex ◽  
Beneficial Effects ◽  
Alcohol Cues ◽  
History Of ◽  
To Receive

Individuals with alcohol use disorder (AUD) show elevated brain metabolism of acetate at the expense of glucose. We hypothesized that a shift in energy substrates during withdrawal may contribute to withdrawal severity and neurotoxicity in AUD and that a ketogenic diet (KD) may mitigate these effects. We found that inpatients with AUD randomized to receive KD (n = 19) required fewer benzodiazepines during the first week of detoxification, in comparison to those receiving a standard American (SA) diet (n = 14). Over a 3-week treatment, KD compared to SA showed lower “wanting” and increased dorsal anterior cingulate cortex (dACC) reactivity to alcohol cues and altered dACC bioenergetics (i.e., elevated ketones and glutamate and lower neuroinflammatory markers). In a rat model of alcohol dependence, a history of KD reduced alcohol consumption. We provide clinical and preclinical evidence for beneficial effects of KD on managing alcohol withdrawal and on reducing alcohol drinking.

scholarly journals Consideration of sex as a biological variable in the translation of pharmacotherapy for stress-associated drug seeking

2021 ◽  
pp. 100364
Author(s):  
Erin L. Martin ◽  
Elizabeth M. Doncheck ◽  
Carmela M. Reichel ◽  
Aimee L. McRae-Clark
Keyword(s):  
Drug Seeking ◽  
Biological Variable

scholarly journals Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Erica N. Grodin ◽  
Spencer Bujarski ◽  
Brandon Towns ◽  
Elizabeth Burnette ◽  
Steven Nieto ◽  
...  
Keyword(s):  
Macrophage Migration Inhibitory Factor ◽  
Alcohol Use Disorder ◽  
Cue Reactivity ◽  
Negative Mood ◽  
Heavy Drinking ◽  
Neural Activation ◽  
Daily Diary Study ◽  
Alcohol Cues ◽  
To Receive ◽  
The Brain

AbstractIbudilast, a neuroimmune modulator which selectively inhibits phosphodiesterases (PDE)-3, -4, -10, and -11, and macrophage migration inhibitory factor (MIF), shows promise as a novel pharmacotherapy for alcohol use disorder (AUD). However, the mechanisms of action underlying ibudilast’s effects on the human brain remain largely unknown. Thus, the current study examined the efficacy of ibudilast to improve negative mood, reduce heavy drinking, and attenuate neural reward signals in individuals with AUD. Fifty-two nontreatment-seeking individuals with AUD were randomized to receive ibudilast (n = 24) or placebo (n = 28). Participants completed a 2-week daily diary study during which they filled out daily reports of their past day drinking, mood, and craving. Participants completed an functional magnetic resonance imaging (fMRI) alcohol cue-reactivity paradigm half-way through the study. Ibudilast did not have a significant effect on negative mood (β = −0.34, p = 0.62). However, ibudilast, relative to placebo, reduced the odds of heavy drinking across time by 45% (OR = 0.55, (95% CI: 0.30, 0.98)). Ibudilast also attenuated alcohol cue-elicited activation in the ventral striatum (VS) compared to placebo (F(1,44) = 7.36, p = 0.01). Alcohol cue-elicited activation in the VS predicted subsequent drinking in the ibudilast group (F(1,44) = 6.39, p = 0.02), such that individuals who had attenuated ventral striatal activation and took ibudilast had the fewest number of drinks per drinking day in the week following the scan. These findings extend preclinical and human laboratory studies of the utility of ibudilast to treat AUD and suggest a biobehavioral mechanism through which ibudilast acts, namely, by reducing the rewarding response to alcohol cues in the brain leading to a reduction in heavy drinking.

Care plans reduce ED visits in those with drug-seeking behavior

2015 ◽  
Vol 33 (12) ◽  
pp. 1799-1801 ◽  
Author(s):  
Frederick Fiesseler ◽  
Renee Riggs ◽  
David Salo ◽  
Richard Klemm ◽  
Ashley Flannery ◽  
...  
Keyword(s):  
Drug Seeking ◽  
Care Plans ◽  
Seeking Behavior ◽  
Ed Visits

scholarly journals Differential Brain Activity in Alcoholics and Social Drinkers to Alcohol Cues: Relationship to Craving

2003 ◽  
Vol 29 (2) ◽  
pp. 393-402 ◽  
Author(s):  
Hugh Myrick ◽  
Raymond F Anton ◽  
Xingbao Li ◽  
Scott Henderson ◽  
David Drobes ◽  
...  
Keyword(s):  
Brain Activity ◽  
Social Drinkers ◽  
Alcohol Cues

scholarly journals Engineering Safer Psychedelics for Treating Addiction

2021 ◽  
Vol 16 ◽  
pp. 263310552110338
Author(s):  
Jamie Peters ◽  
David E Olson
Keyword(s):  
Executive Control ◽  
Neural Circuitry ◽  
Opioid Addiction ◽  
Adult Brain ◽  
Great Promise ◽  
Therapeutic Effects ◽  
Preclinical Models ◽  
Drug Seeking ◽  
Reward Circuitry

Addiction is best described as a disorder of maladaptive neuroplasticity involving the simultaneous strengthening of reward circuitry that drives compulsive drug seeking and weakening of circuits involved in executive control over harmful behaviors. Psychedelics have shown great promise for treating addiction, with many people attributing their therapeutic effects to insights gained while under the influence of the drug. However, psychedelics are also potent psychoplastogens—molecules capable of rapidly re-wiring the adult brain. The advent of non-hallucinogenic psychoplastogens with anti-addictive properties raises the intriguing possibility that hallucinations might not be necessary for all therapeutic effects of psychedelic-based medicines, so long as the underlying pathological neural circuitry can be remedied. One of these non-hallucinogenic psychoplastogens, tabernanthalog (TBG), appears to have long-lasting therapeutic effects in preclinical models relevant to alcohol and opioid addiction. Here, we discuss the implications of these results for the development of addiction treatments, as well as the next steps for advancing TBG and related non-hallucinogenic psychoplastogens as addiction therapeutics.

Sign in / Sign up

Export Citation Format

Share Document